Lund, Sweden – October 2, 2018 – BioInvent International AB (OMXS: BINV) announced it will be presenting two back-to-back posters with its partner Transgene on a new Treg deletion-optimized checkpoint blocking antibody and its targeting oncolytic viral vector at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA). The anti-CTLA-4 antibody-encoding oncolytic viral product candidate is developed for tumor-localized immunotherapy of cancer.

Generation and characterization of a CTLA-4 antibody with improved FcγR-dependent Treg deletion for tumor microenvironment-targeted oncolytic virotherapy of cancer

• Authors: Monika Semmrich, Jean-Baptiste Marchand, Petra Holmkvist, Linda Mårtensson, Ulla-Carin Tornberg, Laetitia Fend, Mathilda Kovacek, Ulla-Carin Tornberg, Ingrid Teige, Andres McAllister, Eric Quéméneur, Björn Frendéus.
• Poster number: P602

Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment  

• Authors: Jean-Baptiste Marchand, Monika Semmrich, Laetitia Fend, Ulla-Carin Tornberg, Nathalie Silvestre, Björn Frendéus, Eric Quéméneur
• Poster number: P615

The posters will be on display from Friday through Saturday, November 9-10 in the Poster Hall (Hall E).

Björn Frendéus, CSO of BioInvent, said: “We are excited to present a potentially safe and more efficacious strategy to combine anti-CTLA-4 and anti-PD-1/PDL1 checkpoint inhibition in the context of oncolytic virotherapy. Building on the abundant clinical validation of checkpoint blockers, oncoviral tumor-localized delivery of our Treg deletion-optimized monoclonal antibody has the potential to improve the therapeutic window for CLTA-4 targeted checkpoint intervention, enabling better tolerated and more effective combination therapy with approved antibodies targeting the PD-1/PD-L1 axis.”

About BioInvent 
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program BI-1206 is currently in a Phase 1/2 for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se 

For further information, please contact:

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.se 

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.